Somatostatin agonists

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

514323, 546199, 546201, A61K 31445, C07D40100

Patent

active

060573384

ABSTRACT:
This invention relates to somatostatin agonist compounds which are potent with high selectivity toward the receptor subtype 2. Compounds of the formula: ##STR1## including pharmaceutically acceptable salts and hydrates thereof are disclosed. These compounds are useful in the treatment of diabetes, cancer, acromegaly, restenosis, depression, irritable bowel syndrome, pain and diabetic retinopathy. Many of the compounds are also orally active.

REFERENCES:
patent: 4242347 (1980-12-01), Huebner
patent: 4310518 (1982-01-01), Freidinger et al.
patent: 5360807 (1994-11-01), Janssens et al.
patent: 5710155 (1998-01-01), Schnorrenberg et al.
patent: 5869489 (1999-02-01), Shah et al.
Chem. Abs., vol. 119, No. 23, p. 69, col. 1, 1993.
Chem. Abs., vol. 128, No. 2, p. 386, col. 1, 1998.
Chem. Abs., vol. 128, No. 19, p. 604, col. 2, 1998.
Betoin et al. "In vitro and in vivo evidence for a tachykinin NK1 receptor antagonist effect of vapreotide, an analgesic cyclic analog of somatostatin" CA 123:26282, 1995.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Somatostatin agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Somatostatin agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Somatostatin agonists will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-1594137

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.